首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1423293篇
  免费   109220篇
  国内免费   3157篇
耳鼻咽喉   20533篇
儿科学   46988篇
妇产科学   38395篇
基础医学   204135篇
口腔科学   36713篇
临床医学   125214篇
内科学   285640篇
皮肤病学   32127篇
神经病学   111422篇
特种医学   58552篇
外国民族医学   660篇
外科学   216181篇
综合类   28876篇
现状与发展   6篇
一般理论   451篇
预防医学   104569篇
眼科学   31754篇
药学   107487篇
  2篇
中国医学   3985篇
肿瘤学   81980篇
  2021年   12575篇
  2019年   12433篇
  2018年   17259篇
  2017年   12998篇
  2016年   14865篇
  2015年   17734篇
  2014年   23745篇
  2013年   34133篇
  2012年   47948篇
  2011年   49571篇
  2010年   29693篇
  2009年   27534篇
  2008年   45230篇
  2007年   47777篇
  2006年   47270篇
  2005年   45820篇
  2004年   44144篇
  2003年   42102篇
  2002年   40702篇
  2001年   67486篇
  2000年   69712篇
  1999年   59003篇
  1998年   16296篇
  1997年   14614篇
  1996年   15006篇
  1995年   14203篇
  1994年   13409篇
  1993年   12336篇
  1992年   45773篇
  1991年   44643篇
  1990年   43258篇
  1989年   41103篇
  1988年   37772篇
  1987年   37041篇
  1986年   34395篇
  1985年   32959篇
  1984年   24656篇
  1983年   20730篇
  1982年   12045篇
  1981年   11006篇
  1979年   21776篇
  1978年   15165篇
  1977年   12854篇
  1976年   11991篇
  1975年   12865篇
  1974年   14950篇
  1973年   14392篇
  1972年   13198篇
  1971年   11920篇
  1970年   11238篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
Dosage form is a mean used for the delivery of drug to a living body. In order to get the desired effect the drug should be delivered to its site of action at such rate and concentration to achieve the maximum therapeutic effect and minimum adverse effect. Since oral route is still widely accepted route but having a common drawback of difficulty in swallowing of tablets and capsules. Therefore a lot of research has been done on novel drug delivery systems. This review is about oral dispersible tablets a novel approach in drug delivery systems that are now a day''s more focused in formulation world, and laid a new path that, helped the patients to build their compliance level with the therapy, also reduced the cost and ease the administration especially in case of pediatrics and geriatrics. Quick absorption, rapid onset of action and reduction in drug loss properties are the basic advantages of this dosage form.  相似文献   
43.
Potential for widespread transmission of HIV/AIDS among American Indian (AI) adolescents exists, yet no evidence-based interventions (EBIs) have been adapted and evaluated with this population. Intensive psychoeducation may improve knowledge and decision-making which could potentially translate to reductions in HIV risk behaviors. A peer group randomized controlled comparison of an adapted EBI vs. control was delivered over an eight-day summer basketball camp in one reservation-based tribal community to adolescents ages 13–19. Outcome data were gathered immediately post-camp and at 6 and 12 months follow-up. Self-selected peer groups were randomized to intervention (n = 138) or control (n = 129) conditions for a total sample of 267 participants (56.2% female), mean age 15.1 years (SD = 1.7). Intervention participants had better condom use self-efficacy post-camp (Adjusted Mean Difference [AMD] = ?0.75, p < 0.005) and at 6 (AMD = ?0.44, p < 0.005) and 12 months (AMD = ?0.23, p < 0.05) follow-up. Intervention participants also had higher HIV prevention and transmission knowledge (post-camp: AMD = 0.07, p < 0.01; 6 months: AMD = 0.06, p < 0.01) were more likely to believe condoms prevent sexually transmitted infections (post-camp: RR = 1.41, p < 0.005; 6 months: RR = 1.34, p < 0.05), to talk with an adult about HIV/AIDS (post-camp: RR=1.78, p < 0.005; 6 months: RR = 1.14, p < 0.005), had higher partner negotiation efficacy related to substance use during sex (post-camp: AMD = 0.37, p < 0.01), and were more likely to intend to use a condom (post-camp: RR = 1.39, p < 0.01). The adapted intervention had short- and medium-term impacts on AI adolescent risk for HIV/AIDS, but attenuated at 12 months. Intervention delivery through a community-based camp is feasible and acceptable with strong retention. Additional study is needed to evaluate the adapted intervention's impact on sexual risk behaviors and if booster sessions and parent involvement translate to long-term impacts.  相似文献   
44.
45.
46.
Bipolar disorder (BD) is a common psychiatric mood disorder affecting more than 1-2% of the general population of different European countries. Unfortunately, there is no objective laboratory-based test to aid BD diagnosis or monitor its progression, and little is known about the molecular basis of BD. Here, we performed a comparative proteomic study to identify differentially expressed plasma proteins in various BD mood states (depressed BD, manic BD, and euthymic BD) relative to healthy controls. A total of 10 euthymic BD, 20 depressed BD, 15 manic BD, and 20 demographically matched healthy control subjects were recruited. Seven high-abundance proteins were immunodepleted in plasma samples from the 4 experimental groups, which were then subjected to proteome-wide expression profiling by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight tandem mass spectrometry. Proteomic results were validated by immunoblotting and bioinformatically analyzed using MetaCore. From a total of 32 proteins identified with 1.5-fold changes in expression compared with healthy controls, 16 proteins were perturbed in BD independent of mood state, while 16 proteins were specifically associated with particular BD mood states. Two mood-independent differential proteins, apolipoprotein (Apo) A1 and Apo L1, suggest that BD pathophysiology may be associated with early perturbations in lipid metabolism. Moreover, down-regulation of one mood-dependent protein, carbonic anhydrase 1 (CA-1), suggests it may be involved in the pathophysiology of depressive episodes in BD. Thus, BD pathophysiology may be associated with early perturbations in lipid metabolism that are independent of mood state, while CA-1 may be involved in the pathophysiology of depressive episodes.  相似文献   
47.
48.
49.
50.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号